Sector News

GW Pharmaceuticals hires investment bank following approaches

September 8, 2016
Life sciences

GW Pharmaceuticals Plc, a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.

The move shows how the Cambridge, England-based company is emerging as a coveted target for larger pharmaceutical companies thanks to its key drug, Epidolex, which uses cannabis-based compounds to treat epilepsy.

GW has hired investment bank Morgan Stanley to help handle the overtures, the people said this week. The company is not currently interested in exploring a sale, and there is no certainty that any deal will occur, the people added.

The identity of the potential suitors could not be established. The sources asked not to be identified because the deliberations are confidential.

GW declined to comment. Morgan Stanley did not respond to a request for comment.

GW shares ended trading in London up 0.6 percent at 526.50 pence (70 U.S. cents), giving the company a market capitalization of 1.6 billion pounds ($2.1 billion). American depositary receipts of the company jumped as much as 22 percent in New York following the Reuters report.

GW’s move is the latest sign that dealmaking in the biotechnology sector is picking up. Last month, Pfizer Inc clinched a $14 billion acquisition of U.S. cancer drug company Medivation Inc.

Major players in the market for central nervous system treatments, including Allergan Plc and Biogen Inc , are searching for deals to build out their commercial presence and research and development pipelines.

Logical buyers for GW would include the companies that have partnered with it to distribute its marketed drug, Sativex, a nasal spray for multiple sclerosis that is also based on marijuana, one of the people said.

GW’s current partners include Novartis AG, Bayer AG and Almirall SA, among others.

Epidolex is in late-stage clinical trials and could receive approval from the U.S. Food and Drug Administration as soon as next year. It could eventually produce annual sales in excess of $800 million, according analysts at investment bank Cowen & Co.

The drug’s success is especially important to GW because of the tepid performance of Sativex, which has been marketed since 2010.

Sativex was never approved in the United States, and only produced $2 million in sales in the latest financial quarter.

GW Pharma is also exploring early-stage treatments for other illnesses, including diabetes and schizophrenia.

By Carl O’Donnell and Arno Schuetze

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.